Literature DB >> 27998977

The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.

Delia Susan-Resiga1, Emmanuelle Girard1, Robert Scott Kiss2, Rachid Essalmani1, Josée Hamelin1, Marie-Claude Asselin1, Zuhier Awan1, Chutikarn Butkinaree1, Alexandre Fleury3, Armand Soldera3, Yves L Dory3, Alexis Baass4, Nabil G Seidah5.   

Abstract

Familial hypercholesterolemia (FH) is characterized by severely elevated low density lipoprotein (LDL) cholesterol. Herein, we identified an FH patient presenting novel compound heterozygote mutations R410S and G592E of the LDL receptor (LDLR). The patient responded modestly to maximum rosuvastatin plus ezetimibe therapy, even in combination with a PCSK9 monoclonal antibody injection. Using cell biology and molecular dynamics simulations, we aimed to define the underlying mechanism(s) by which these LDLR mutations affect LDL metabolism and lead to hypercholesterolemia. Our data showed that the LDLR-G592E is a class 2b mutant, because it mostly failed to exit the endoplasmic reticulum and was degraded. Even though LDLR-R410S and LDLR-WT were similar in levels of cell surface and total receptor and bound equally well to LDL or extracellular PCSK9, the LDLR-R410S was resistant to exogenous PCSK9-mediated degradation in endosomes/lysosomes and showed reduced LDL internalization and degradation relative to LDLR-WT. Evidence is provided for a tighter association of LDL with LDLR-R410S at acidic pH, a reduced LDL delivery to late endosomes/lysosomes, and an increased release in the medium of the bound/internalized LDL, as compared with LDLR-WT. These data suggested that LDLR-R410S recycles loaded with its LDL-cargo. Our findings demonstrate that LDLR-R410S represents an LDLR loss-of-function through a novel class 8 FH-causing mechanism, thereby rationalizing the observed phenotype.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  LDL receptor; cell biology; cholesterol metabolism; familial hypercholesterolemia; human natural mutations; loss-of-function; low density lipoprotein (LDL); lysosome; proprotein convertase subtilisin/kexin type 9 (PCSK9); subcellular localization

Mesh:

Substances:

Year:  2016        PMID: 27998977      PMCID: PMC5290936          DOI: 10.1074/jbc.M116.769430

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  Structure of the LDL receptor extracellular domain at endosomal pH.

Authors:  Gabby Rudenko; Lisa Henry; Keith Henderson; Konstantin Ichtchenko; Michael S Brown; Joseph L Goldstein; Johann Deisenhofer
Journal:  Science       Date:  2002-11-29       Impact factor: 47.728

2.  GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit.

Authors:  Sander Pronk; Szilárd Páll; Roland Schulz; Per Larsson; Pär Bjelkmar; Rossen Apostolov; Michael R Shirts; Jeremy C Smith; Peter M Kasson; David van der Spoel; Berk Hess; Erik Lindahl
Journal:  Bioinformatics       Date:  2013-02-13       Impact factor: 6.937

Review 3.  The LDL receptor: how acid pulls the trigger.

Authors:  Natalia Beglova; Stephen C Blacklow
Journal:  Trends Biochem Sci       Date:  2005-06       Impact factor: 13.807

4.  Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Maryse Guerin; Suzanne Benjannet; Jean-Pierre Rabès; Wilfried Le Goff; Zélie Julia; Josée Hamelin; Valérie Carreau; Mathilde Varret; Eric Bruckert; Laurent Tosolini; Olivier Meilhac; Philippe Couvert; Dominique Bonnefont-Rousselot; John Chapman; Alain Carrié; Jean-Baptiste Michel; Annik Prat; Nabil G Seidah; Catherine Boileau
Journal:  Atherosclerosis       Date:  2012-05-17       Impact factor: 5.162

5.  Quantitative proteomic analysis of PCSK9 gain of function in human hepatic HuH7 cells.

Authors:  Nicholas Denis; Heather Palmer-Smith; Fred Elisma; Alia Busuttil; Theodore Glenn Wright; Maroun Bou Khalil; Annik Prat; Nabil G Seidah; Michel Chrétien; Janice Mayne; Daniel Figeys
Journal:  J Proteome Res       Date:  2011-03-10       Impact factor: 4.466

6.  Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.

Authors:  Chutikarn Butkinaree; Maryssa Canuel; Rachid Essalmani; Steve Poirier; Suzanne Benjannet; Marie-Claude Asselin; Anna Roubtsova; Josée Hamelin; Jadwiga Marcinkiewicz; Ann Chamberland; Johann Guillemot; Gaétan Mayer; Sangram S Sisodia; Yves Jacob; Annik Prat; Nabil G Seidah
Journal:  J Biol Chem       Date:  2015-06-17       Impact factor: 5.157

7.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

8.  Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Authors:  Kara N Maxwell; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

Review 9.  PCSK9: a key modulator of cardiovascular health.

Authors:  Nabil G Seidah; Zuhier Awan; Michel Chrétien; Majambu Mbikay
Journal:  Circ Res       Date:  2014-03-14       Impact factor: 17.367

10.  Improved side-chain torsion potentials for the Amber ff99SB protein force field.

Authors:  Kresten Lindorff-Larsen; Stefano Piana; Kim Palmo; Paul Maragakis; John L Klepeis; Ron O Dror; David E Shaw
Journal:  Proteins       Date:  2010-06
View more
  10 in total

1.  Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).

Authors:  Ali Ben Djoudi Ouadda; Marie-Soleil Gauthier; Delia Susan-Resiga; Emmanuelle Girard; Rachid Essalmani; Miles Black; Jadwiga Marcinkiewicz; Diane Forget; Josée Hamelin; Alexandra Evagelidis; Kevin Ly; Robert Day; Luc Galarneau; Francois Corbin; Benoit Coulombe; Artuela Çaku; Vincent S Tagliabracci; Nabil G Seidah
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-09-05       Impact factor: 8.311

2.  The motif EXEXXXL in the cytosolic tail of the secretory human proprotein convertase PC7 regulates its trafficking and cleavage activity.

Authors:  Loreleï Durand; Stéphanie Duval; Alexandra Evagelidis; Johann Guillemot; Vahid Dianati; Emilia Sikorska; Peter Schu; Robert Day; Nabil G Seidah
Journal:  J Biol Chem       Date:  2020-01-08       Impact factor: 5.157

3.  Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9.

Authors:  Sonia Nava-Salazar; Arturo Flores-Pliego; Giovanni Pérez-Martínez; Sandra Parra-Hernández; America Vanoye-Carlo; Francisco Ibarguengoitia-Ochoa; Otilia Perichart-Perera; Enrique Reyes-Muñoz; Juan Mario Solis-Paredes; Salvador Espino Y Sosa; Guadalupe Estrada-Gutierrez
Journal:  Reprod Sci       Date:  2022-04-25       Impact factor: 3.060

4.  Proprotein convertase subtilisin/kexin type 9 inhibitor non responses in an adult with a history of coronary revascularization: A case report.

Authors:  Liu Yang; Yan-Yan Xiao; Liang Shao; Chang-Sheng Ouyang; Yao Hu; Bin Li; Li-Feng Lei; Hong Wang
Journal:  World J Clin Cases       Date:  2022-07-06       Impact factor: 1.534

Review 5.  The Multifaceted Biology of PCSK9.

Authors:  Nabil G Seidah; Annik Prat
Journal:  Endocr Rev       Date:  2022-05-12       Impact factor: 25.261

6.  Montreal-FH-SCORE Predicts Coronary Artery Calcium Score in Patients With Familial Hypercholesterolemia.

Authors:  Sarah Béland-Bonenfant; Martine Paquette; Manon Fantino; Lucienne Bourque; Nathalie Saint-Pierre; Alexis Baass; Sophie Bernard
Journal:  CJC Open       Date:  2020-09-14

7.  Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies.

Authors:  Carlota Oleaga; Michael D Shapiro; Joshua Hay; Paul A Mueller; Joshua Miles; Cecilia Huang; Emily Friz; Hagai Tavori; Peter P Toth; Cezary Wójcik; Bruce A Warden; Jonathan Q Purnell; P Barton Duell; Nathalie Pamir; Sergio Fazio
Journal:  J Am Coll Cardiol       Date:  2021-10-05       Impact factor: 24.094

8.  Identification of New Genetic Determinants in Pediatric Patients with Familial Hypercholesterolemia Using a Custom NGS Panel.

Authors:  Lena Rutkowska; Kinga Sałacińska; Dominik Salachna; Paweł Matusik; Iwona Pinkier; Łukasz Kępczyński; Małgorzata Piotrowicz; Ewa Starostecka; Andrzej Lewiński; Agnieszka Gach
Journal:  Genes (Basel)       Date:  2022-06-01       Impact factor: 4.141

9.  New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia.

Authors:  Sandy Elbitar; Delia Susan-Resiga; Youmna Ghaleb; Petra El Khoury; Gina Peloso; Nathan Stitziel; Jean-Pierre Rabès; Valérie Carreau; Josée Hamelin; Ali Ben-Djoudi-Ouadda; Eric Bruckert; Catherine Boileau; Nabil G Seidah; Mathilde Varret; Marianne Abifadel
Journal:  Sci Rep       Date:  2018-01-31       Impact factor: 4.379

Review 10.  Proteostasis Regulation in the Endoplasmic Reticulum: An Emerging Theme in the Molecular Pathology and Therapeutic Management of Familial Hypercholesterolemia.

Authors:  Deepu Oommen; Praseetha Kizhakkedath; Aseel A Jawabri; Divya Saro Varghese; Bassam R Ali
Journal:  Front Genet       Date:  2020-09-23       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.